Xbrane Biopharma AB (publ) (STO: XBRANE)

Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	30.59	65.4	193.99	295.18	243.14	164.2
Cash & Short-Term Investments	30.59	65.4	193.99	295.18	243.14	164.2
Cash Growth	-81.71%	-66.29%	-34.28%	21.40%	48.08%	62.62%
Accounts Receivable	79.69	-	1.34	-	51.38	-
Other Receivables	122.03	71.18	46.12	108.3	23.79	17.07
Receivables	201.72	71.18	47.46	108.3	75.17	17.07
Inventory	212.97	106.86	50.26	-	-	-
Prepaid Expenses	9.46	16.89	13	2.31	1.21	0.64
Other Current Assets	184.3	201.37	208.81	155.21	54.96	66.03
Total Current Assets	639.03	461.69	513.52	561.01	374.48	247.94
Property, Plant & Equipment	70.73	88.2	71.05	73.8	14.14	16.21
Goodwill	-	-	-	-	58.45	60.76
Long-Term Deferred Charges	125.96	99.67	102	49.67	4.08	5.05
Other Long-Term Assets	3.95	3.95	3.95	3.95	12.61	8.98
Total Assets	839.67	653.51	690.52	688.43	463.76	338.94
Accounts Payable	194.72	30.97	23.3	41.39	29.55	21.1
Accrued Expenses	103.55	59.23	66.48	65.76	41.22	27.01
Current Portion of Long-Term Debt	52.08	62.5	-	-	-	0.01
Current Portion of Leases	12.91	13.37	9.16	7.91	2.27	3.14
Current Unearned Revenue	-	159.6	136.06	95.39	115.96	111.59
Other Current Liabilities	110.89	0.88	1.56	9.22	0	1.73
Total Current Liabilities	474.16	326.56	236.57	219.67	188.99	164.59
Long-Term Debt	72.1	112.9	-	-	-	-
Long-Term Leases	33.26	42.71	29.06	36.48	4	6.28
Long-Term Unearned Revenue	-	-	-	0.54	8.26	-
Other Long-Term Liabilities	-0	0.01	-	-	4.81	8.72
Total Liabilities	579.52	482.17	265.63	256.69	206.06	179.59
Common Stock	342.89	6.68	6.17	5.61	4.98	3.46
Additional Paid-In Capital	1,394	1,429	1,294	1,134	773.72	448.09
Retained Earnings	-1,487	-1,274	-885.83	-713.31	-524.94	-298.91
Comprehensive Income & Other	10.18	10.12	10.32	5.16	3.95	6.72
Shareholders' Equity	260.15	171.34	424.89	431.74	257.71	159.35
Total Liabilities & Equity	839.67	653.51	690.52	688.43	463.76	338.94
Total Debt	170.36	231.48	38.22	44.38	6.26	9.44
Net Cash (Debt)	-139.77	-166.08	155.77	250.8	236.88	154.76
Net Cash Growth	-	-	-37.89%	5.88%	53.06%	179.50%
Net Cash Per Share	-0.16	-5.79	6.09	10.63	13.08	13.83
Filing Date Shares Outstanding	1,529	29.81	27.51	25.04	22.2	15.42
Total Common Shares Outstanding	1,529	29.81	27.51	25.04	22.2	15.42
Working Capital	164.87	135.14	276.96	341.34	185.49	83.35
Book Value Per Share	0.17	5.75	15.45	17.24	11.61	10.34
Tangible Book Value	260.15	171.34	424.89	431.74	199.26	98.59
Tangible Book Value Per Share	0.17	5.75	15.45	17.24	8.98	6.40
Machinery	-	61.93	-	43.49	28.4	25.02
Construction In Progress	-	-	-	-	-	0.11

Source: S&P Capital IQ. Standard template. Financial Sources.